Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950856 · ClinicalTrials.gov registry record · Phase 3
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,340
- Enrollment target
NCT03950856 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 2,340 participants.
The verdict
NCT03950856, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,340 participants
- Enrollment target
Study Summary
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114. The primary hypothesis is that all 3 lots of V114 are equivalent as measured by the serotype-specific OPA GMTs for 15 serotypes in V114 at 30 days postvaccination.
Interventions
- DRUG V114
- DRUG Prevnar 13™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,340 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950856
The ClinicalTrials.gov registry entry for NCT03950856 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which V114 is the first listed.
NCT03950856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03950856 about?
NCT03950856 is a clinical study titled "Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)". The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114. The primary hypothesis is that all 3 lots of V114 are equivalent as measured by the serotype-s...
What is the current status of trial NCT03950856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,340 participants. The study started on 2019-06-12. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03950856?
The interventions under investigation include: V114 (DRUG), Prevnar 13™ (DRUG).
Who is sponsoring clinical trial NCT03950856?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.